| NCT05329545 | III | High grade serous NaPi2b+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy; no avastin with most recent platinum-based therapy (maintenance) | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT) | AZ, CA, CO, FL, GA, IL, LA, ME, MD, MI, MN, MO, MT, NE, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WI | View Drugs | View Results |
Placebo | | | | Upifitamab rilsodotin | XMT-1536, UpRi | ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA) | Clinical Trials |
|
|
| NCT05445778 | III | High grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after second line platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance) | Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab | LA, NV, NY, NC | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Mirvetuximab soravtansine | Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4 | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Approved in Ovarian Cancer |
|
|
| NCT04804007 | II | Germ cell tumors after treatment with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) (maintenance) | Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor | IN | View Drugs | |
Etoposide | VePesid, Toposar, Lastet, epipodophyllotoxin | Topoisomerase II inhibitor | |
|
|
| NCT04853017 | I | Advanced solid tumors with KRAS/NRAS mutation (G12D or G12R) with minimal residual disease after treatment | First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors | CA, CO, IA, MA, NY, TX | View Drugs | |
ELI-002 | | Immune response against cancer expressing KRAS G12D, G12R or NRAS G12D, G12R | Clinical Trials |
|
|